Mirum Pharmaceuticals (MIRM) Earnings Date & Reports

Key Takeaways

• Mirum reported third quarter 2026 net product sales of $185.7 million, up 39.6% year over year and ahead of consensus estimates near $176–178 million.
• Diluted EPS (earnings per share) came in at a loss of -$0.87, below consensus expectations, as the company sharply increased research and development spending.
• LIVMARLI net product sales reached $133.4 million, while bile acid medicines contributed $52.3 million, both posting double-digit growth.
• Management raised full-year 2026 net product sales guidance to $715–$720 million, above its prior outlook.
• The company's newest medicine, ATEBRIOZ for FOP (fibrodysplasia ossificans progressiva), launched in the U.S. in October following its September approval.
• For more details on this ticker, explore its Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Looking for trade ideas across the broader market? Explore Trending AI Robots for AI-driven signals and market opportunities.

Earnings Context and Why It Matters

Mirum Pharmaceuticals is a rare-disease biopharmaceutical company focused on rare liver and rare genetic conditions. Its commercial portfolio has expanded from one product to four approved medicines in recent years, making each quarterly report a key checkpoint on both revenue growth and the spending behind a broadening pipeline. The third quarter of 2026 marked the first full period following several important milestones, including the approval of ATEBRIOZ for FOP and positive late-stage data from the brelovitug and LIVMARLI programs. For investors, the results matter because they show whether strong commercial momentum can keep pace with a heavier investment cycle, and whether the company's push toward multiple future approvals is translating into durable top-line expansion.

Reported Results

Mirum reported third quarter 2026 total net product sales of $185.7 million, a 39.6% increase from the prior-year period and above the consensus estimate of roughly $176–178 million. LIVMARLI (maralixibat), used to treat Alagille syndrome and PFIC (progressive familial intrahepatic cholestasis), generated $133.4 million in net product sales, up about 45% year over year. Bile acid medicines, comprising CHOLBAM and CTEXLI, added $52.3 million, up approximately 28%.

On the bottom line, the company posted a diluted loss of -$0.87 per share, wider than consensus estimates and a reversal from the small profit reported a year earlier. The swing largely reflected higher spending: research and development expenses rose to about $107.9 million from $43.0 million in the prior-year quarter, while selling, general, and administrative expenses climbed to roughly $88.9 million. The quarter's R&D (research and development) outlays included development costs tied to brelovitug as well as acquired in-process research and development expenses.

Mirum raised its full-year 2026 net product sales guidance to a range of $715–$720 million, an increase from its prior outlook and above the analyst consensus of approximately $698 million at the time.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Mirum Pharmaceuticals, it offers a structured way to surface comparable opportunities and monitor shifting market conditions. Consider exploring the AI Screener to complement your own research workflow.

Market Reaction and Investor Sentiment

Market reaction to the report reflected a mixed picture. Revenue beat expectations and guidance was raised, yet the wider-than-expected per-share loss highlighted the near-term cost of the company's pipeline investments. That combination — strong demand offset by heavier spending — typically leaves investors weighing commercial momentum against profitability timing. Heading into the report, sentiment had been supported by a series of clinical milestones, including positive Phase 3 data for brelovitug and the approval of ATEBRIOZ. The key risk factors investors continue to monitor are the pace of R&D escalation, the durability of LIVMARLI growth, and how quickly the company can convert its late-stage pipeline into approvals and commercial launches.

Forward Outlook and Key Factors to Monitor

Looking ahead, Mirum's management pointed to several near-term catalysts. The company expects brelovitug data from the AZURE-4 study in HDV (hepatitis delta virus, a severe form of viral hepatitis) during the fourth quarter, and volixibat data from the VANTAGE study in PBC (primary biliary cholangitis) in the first quarter of 2027.

Investors should also watch the trajectory of the ATEBRIOZ launch in FOP, which began in October, and the planned regulatory submissions the company has outlined. Management cited five potential approvals and label expansions ahead, including submissions for volixibat, brelovitug, and a supplemental filing for LIVMARLI based on the EXPAND study.

On the financial side, the key question is whether gross profit from the growing commercial base can eventually absorb the higher R&D bill. The company ended the quarter with unrestricted cash and investments of about $500 million, providing resources to fund continued development. Margin trends, expense discipline, and the pacing of clinical readouts will be the central factors to monitor over the coming quarters.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations